

GNIPST BULLETIN 2024

(Pharmacy)



VOLUME-1, ISSUE- 6
(Final Issue)



GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

1 Message from Director and Principal 2

2 Recent Researches 3

3 New Drug Approvals 4

4 Clinical Trial News 5

5 Disease Outbreak News 6

6 Campus News 7

7 Special Pages 8

8 Game Time 9





MESSAGE FROM HONORABLE DIRECTOR

I extend my heartfelt greetings to you all. At Guru Nanak Institute of Pharmaceutical Science and Technology, we are committed to fostering an environment of academic excellence, innovation and holistic development. Our institution is dedicated in pursuit of Pharmaceutical Sciences.

We believe in nurturing inquisitive minds, encouraging critical thinking and developing skills of our beloved students. As we continue to grow and evolve, we remain steadfast in our mission to provide quality education and promote research and innovation. We wholeheartedly appreciate your valued presence and involvement with Guru Nanak Institute of Pharmaceutical Science and Technology.

Prof. (Dr.) Abhijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

It is my great pleasure to extend a warm welcome to you to Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST). GNIPST is among the leading educational institutes of West Bengal aiming to provide quality pharmacy education to students.

GNIPST was established in 2005 and approved by PCI and affiliated to Maulana Abul Kalam Azad University of Technology, West Bengal. The institute is also the first pharmacy institute in West Bengal to receive accreditation from NAAC and NBA and the only private Pharmacy Autonomous institute in West Bengal. GNIPST is proud to be an NIRF Ranked Pharmacy Institute, being the 87th ranked institute in 2023.

We sincerely believe that rich values and traditions imbibed here along with proper educational facilities would carry the students to greater levels in their life.

Choose PHARMACY as a career and join with us to have a academically rewarding student life at GNIPST.

Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



Statement of the fortieth meeting of the Polio IHR Emergency Committee, 3rd December 2024

[READ MORE](#)

<https://www.who.int>

WHO announces first prequalification of a tuberculosis diagnostic test, 5th December

[READ MORE](#)

<https://www.who.int/news/item/05-12-2024-who-announces-first-prequalification-of-a-tuberculosis-diagnostic-test>

Over 1 in 5 adults worldwide has a genital herpes infection – WHO, 11th Dec 2024

[READ MORE](#)

<https://www.who.int>

Partnership established to advance WHO's Road map for Neglected Tropical Diseases 2021-2030, 11th Dec 2024

[READ MORE](#)

<https://www.who.int>

The fortieth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 6 November 2024 with Committee members and advisers meeting via video conference with affected countries, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global target of interruption and certification of WPV1 eradication by 2027 and interruption and certification of cVDPV2 elimination by 2029. Technical updates were received about the situation in Afghanistan, Cameroon, France, Ghana, Indonesia, Nigeria, occupied Palestinian territory (oPt), Pakistan, Spain and Zimbabwe.

The World Health Organization (WHO) has granted prequalification to the molecular diagnostic test for tuberculosis (TB) called Xpert® MTB/RIF Ultra. It is the first test for TB diagnosis and antibiotic susceptibility testing that meets WHO's pre qualification standards. WHO's assessment for prequalification is based on information submitted by the manufacturer, Cepheid Inc., and the review by Singapore's Health Sciences Authority (HSA), the regulatory agency of record for this product. In a joint effort by WHO Global TB Programme and the Department of Regulation and Prequalification to improve access to quality-assured TB tests and expand diagnostic options for countries, WHO is currently assessing seven additional TB tests.

Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today. At least 1 person each second – 42 million people annually – is estimated to acquire a new genital herpes infection. In line with its Global Health Sector Strategy on HIV, viral hepatitis and sexually transmitted infections for 2022-2030, WHO works to increase awareness about genital herpes infections and related symptoms, improve access to antiviral medications, and promote related HIV prevention efforts. It is also working to advance research and development of new tools for the prevention and control of herpes infections, such as vaccines, treatments and topical microbicides.

The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to further expand their partnership to promote access to safe, effective and affordable drugs, vaccines and diagnostics in the area of neglected tropical diseases (NTDs). The MoU makes provision for four areas of collaboration: (i) research and development aimed at strengthening the arsenal of innovative tools, treatments and interventions for NTDs; (ii) resource mobilization, notably through the development of an NTD investment case toolkit and sustainable procurement systems; (iii) advocacy and awareness, to raise the profile of NTDs within global and local health agendas; and (iv) participation of GHIT as observers in NTD working groups and task forces convened by WHO

NEW DRUG APPROVALS



Danziten (nilotinib tartrate) Tablets

- **Company:** Azurity Pharmaceuticals, Inc.
- **Date of Approval:** November 7, 2024
- **Treatment for:** Chronic Myelogenous Leukemia

1

Revuforj (revumenib) Tablets

- **Company:** Syndax Pharmaceuticals, Inc.
- **Date of Approval:** November 15, 2024
- **Treatment for:** Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

2

Ziihera (zanidatamab-hrij) Lyophilized Powder for Injection

- **Company:** Jazz Pharmaceuticals plc
- **Date of Approval:** November 20, 2024
- **Treatment for:** Biliary Tract Tumor

3

Imkeldi (imatinib mesylate) Oral Solution

- **Company:** Shorla Oncology Inc.
- **Date of Approval:** November 22, 2024
- **Treatment for:** Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Diseases.

4

Attruby (acoramidis) Tablets

- **Company:** BridgeBio Pharma, Inc.
- **Date of Approval:** November 22, 2024
- **Treatment for:** Cardiomyopathy of Transthyretin-Mediated Amyloidosis

5

Yesintek (ustekinumab-kfce) Injection

- **Company:** Biocon Biologics Ltd.
- **Date of Approval:** November 29, 2024
- **Treatment for:** Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis

6

LEARN

MORE

<https://www.drugs.com/newdrugs.html>

GNIPST BULLETIN 2024



CLINICAL TRIAL NEWS

NOVEMBER 2024



1. Newer Epilepsy Medications Used During Pregnancy Do Not Affect Neurological Development in Children

November 27, 2024 -- Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study funded by the National Institutes of Health (NIH). The study was published in JAMA Neurology.

2. Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering innovative therapies for the management of central nervous system (CNS) disorders, today announced that AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint in the ENCORE Phase 3 trial, demonstrating a statistically significant improvement in the frequency of cataplexy attacks compared to placebo. AXS-12 was also well tolerated with long-term dosing with a safety profile consistent with that observed in previously completed trials. ENCORE was a multi-center, two-period Phase 3 trial evaluating the long-term efficacy and safety of AXS-12 in patients with narcolepsy with cataplexy, consisting of a 6-month open-label AXS-12 treatment period, followed by a 3-week double-blind, placebo-controlled, randomized withdrawal period. The trial enrolled 68 patients in the 6-month AXS-12 treatment period. Patients (n=42) were then randomized in a 1:1 ratio to continue treatment with AXS-12 or to discontinue AXS-12 and switch to placebo for 3 weeks.



axsome

3. Cassava Sciences Topline Phase 3 Data for Simufilam Did Not Meet Co-Primary Endpoints

AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer's disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. Simufilam continued to demonstrate an overall favorable safety profile. The Company will hold a webcast today at 8 AM ET.



4. Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

CHANHASSEN, Minn., Nov. 24, 2024. Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced positive results from their Phase 1/2 clinical trial in patients with recurrent or refractory high-grade gliomas. The company's proprietary therapy demonstrated a strong safety profile and extended median overall survival (OS) and progression-free survival (PFS) compared to historical data. The data were presented by Michael Schulder, MD, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting.



5. Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2024-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington's Disease (HD). In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84. Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo. Based on these results, the Company does not plan further development of dalzanemdor.



6. Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease.



DISEASE OUTBREAK NEWS



1. Marburg virus disease - Rwanda


13 November 2024

Situation at a glance

On 9 November 2024, the recommended 42-day countdown to declare the end of the Marburg virus disease (MVD) outbreak in Rwanda commenced, the day after the last confirmed patient tested negative for MVD by polymerase chain reaction (PCR). As of 8 November 2024, 66 confirmed cases, including 15 deaths with a case fatality ratio (CFR) of 23% have been reported and 51 confirmed cases have recovered. The country has reported no new confirmed cases since 30 October 2024. The outbreak will only be declared over if no new infections arise during the 42-day countdown. WHO continues to support the Government of Rwanda in responding to the outbreak. Enhanced surveillance, and infection prevention and control (IPC) measures must be maintained until the outbreak is declared over.



<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON538>




<https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON544>

2. Oropouche virus disease - Region of the Americas

5 December 2024

Situation at a glance

Since the last Disease Outbreak News on this event was published on 23 August 2024, three additional countries and one territory (Ecuador, Guyana, Panama and Cayman Island) have reported confirmed Oropouche virus disease in the Region of the Americas in 2024. In addition, imported Oropouche cases have been reported from Canada, the United States of America and countries of the European Region. As of 25 November 2024, a total of 11 634 confirmed Oropouche cases, including two deaths, have been reported in the Region of the Americas, across ten countries and one territory: Bolivia (Plurinational State of), Brazil, Canada, Cayman Islands, Colombia, Cuba, Ecuador, Guyana, Panama, Peru and the United States of America. Based on available information, WHO assesses the overall public health risk posed by this virus to be high at the regional level and low at the global level. As the arbovirus season is starting in the region, WHO urges countries at risk to strengthen epidemiological and entomological surveillance and to reinforce preventive measures in the population. This is crucial due to the geographical expansion of the virus and the possible new vectors and transmission routes, including vertical transmission, that could affect both the general population and vulnerable groups, such as pregnant women, their fetuses, and newborns.



GNIPST BULLETIN 2024





INSTITUTE OF
PHARMACEUTICAL
SCIENCE & TECHNOLOGY

Campus News



World Diabetes Day 2024,

GNIPST in collaboration with GNIDSR is organizing a Dental Check-up Camp and a Seminar to raise awareness about the link between diabetes and oral health. The event aims to educate the community on prevention and



Vedanta Course on 18.11.2024

The Second Class of the Vedanta Course on 18.11.2024 was truly enlightening! We delved into the topic Children of Immortal Bliss and celebrated the Release of New Book: Mind Your Mind.



National Constitution Day (26.11.24)

On 26th November, GNIPST celebrated Constitution Day, honoring the adoption of India's Constitution. The event highlighted the significance of democratic values, equality, and justice. Students and faculty engaged in discussions and activities, reinforcing the importance of constitutional rights and duties in shaping a vibrant nation.



Student Achievements

Debanjan Bhattacharya and Ayan Pal showcased their skills and knowledge at the prestigious national event, where they ranked among the top 8 teams.



Annual Sport Meet

Guru Nanak Institute of Pharmaceutical Technology hosted an exciting intra-college sports event for students, faculty, and staff. The spirited competition featured badminton, chess, table tennis, football, athletics, fitness, and teamwork. The winners were to be sent for the JIS Spirit 2025. The vibrant campus atmosphere celebrated sportsmanship and unity, making the event a memorable experience for all participants.



JIS inter-college sports

JIS group hosted an electrifying inter-college sports championship across its campuses, bringing together students, faculty, and staff. The event featured thrilling competitions of badminton, chess, table tennis, football.

It celebrated talent, sportsmanship, and unity, fostering healthy competition and camaraderie among participants from various institutions under the JIS banner. Arnab Gon, a student of M.Sc Biotechnology 2nd year, was named Man of the Tournament, Souparna Dutta, a student of B.Sc Biotechnology 2nd year, was the Top scorer, Manabendra Paik, a D.Pharm 1st-year student, who was named Man of the Match in the Final, of the Sardar Jodh Singh Memorial Football Tournament.



Painting Competition

On 07.11.2024, GNIPST successfully organized a Painting Competition as part of the WILD & Wise: A Three-Day Celebration. The event showcased incredible talent and creativity, highlighting the beauty of nature and wildlife.



GNIPST Scholastic Book Fair

The GNIPST Scholastic Book Fair had been a fantastic celebration of knowledge and creativity of our Wild and Wise: A Three-Day Celebration.



For more information www.gnipst.ac.in

GNIPST BULLETIN 2024



Christmas Day: A Celebration of Love and Hope

Christmas Day, celebrated annually on December 25th, is a joyous occasion commemorating the birth of Jesus Christ, who is revered as the central figure of Christianity. This day holds deep spiritual significance for Christians worldwide and is marked by festive traditions, family gatherings, and acts of generosity. Originating in the 4th century, Christmas has transcended religious boundaries, becoming a universal celebration of goodwill and togetherness.



Significance of Christmas Day:

- **Spiritual Reflection:** Christmas symbolises the birth of Jesus Christ, representing divine love, salvation, and hope for humanity.
- **Family Bonding:** It encourages families to come together, promoting love, gratitude, and unity.
- **Acts of Kindness:** The season promotes generosity, compassion, and the spirit of giving, especially towards those in need.
- **Renewal of Faith:** Christmas serves as a reminder to renew one's faith, values, and commitment to living with purpose.
- **Cultural Festivity:** Beyond its religious roots, Christmas has become a time for cultural celebration, marked by decorations, music, and festive meals.

The celebration includes traditions such as decorating Christmas trees, exchanging gifts, attending church services, and singing carols. Santa Claus, a popular figure of folklore, embodies the joy of giving during this festive season.



Game Time

Cross Word

CHRISTMAS CROSSWORD PUZZLE

A	N	A	E	M	I	A
L	E	P	R	O	S	Y
L	O	N	I	T	U	H
E	D	E	C	K	L	X
R	G	U	K	W	F	B
G	L	M	E	A	E	C
Y	S	O	T	N	Q	P
S	A	N	S	M	E	I
Q	W	I	U	G	S	L
R	O	A	L	C	V	B

Answer for Word Search (Volume 1 Issue 5)



Shout out to the "Game Time" Winner of Volume 1, Issue 5 !

Arindom Mondal

B. Pharm, 2nd year 3rd semester

Guru Nanak Institute of Pharmaceutical Science and Technology

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



or

CLICK
HERE



Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com

